Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2005 Oct 22;331(7522):915-6.
doi: 10.1136/bmj.331.7522.915.

Cervical cancer, human papillomavirus, and vaccination

Catherine M Lowndes, O Noel Gill
Editorial

Cervical cancer, human papillomavirus, and vaccination

Catherine M Lowndes et al. BMJ. .

Erratum in

  • BMJ. 2005 Nov 12;331(7525):1120
No abstract available

PubMed Disclaimer

Comment in

References

    1. Merck Newsroom. Merck's investigational vaccine GARDASIL™ prevented 100 per cent of cervical pre-cancers and non-invasive cervical cancers associated with HPV types 16 and 18 in new clinical study. Press release 6 Oct 2005. www.merck.com/newsroom/press_releases/research_and_development/2005_1006... (accessed 17 Oct 2005).
    1. World Health Organization. WHO consultation on human papillomavirus vaccines. Wkly Epidemiol Rec 2005;80: 299-301. - PubMed
    1. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 2002;347: 1645-51. - PubMed
    1. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364: 1757-65. - PubMed
    1. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6: 271-8. - PubMed

Publication types

MeSH terms